Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial

Nancy E Lane, Sarah Sanchez, Gunnar W. Modin, Harry K. Genant, Elena Pierini, Claude D. Arnaud

Research output: Contribution to journalArticle

450 Citations (Scopus)

Abstract

Corticosteroid-induced osteoporosis is the most common secondary cause of osteoporosis. We conducted a 12-mo, randomized clinical trial of human parathyroid hormone 1-34 (hPTH 1-34) in postmenopausal women (mean age was 63 yr) with osteoporosis who were taking corticosteroids and hormone replacement therapy. Response to the treatment was assessed with bone mineral density (BMD) measurements of the lumbar spine by quantitative computed tomography (QCT); BMD measurements of the lumbar spine, hip, and forearm by dual-energy x-ray absorptiometry (DXA); and biochemical markers of bone turnover. The mean (±SE) changes in BMD of the lumbar spine by QCT and DXA in the PTH group were 35±5.5% and 11±1.4%, respectively, compared with a relatively small change of 1.7±1.8% and 0±0.9% in the estrogen-only group. The differences in mean percentage between the groups at 1 yr were 33.5% for the lumbar spine by QCT (P < 0.001) and 9.8% for the lumbar spine by DXA (P < 0.001). The changes in the hip and forearm were not significantly different between or within the groups. During the first 3 mo of PTH treatment, markers of bone formation increased to nearly 150%, whereas markers of bone resorption increased only 100%, suggesting an early uncoupling of bone turnover in favor of formation. These results suggest that parathyroid hormone dramatically increases bone mass in the central skeleton of postmenopausal women with corticosteroid-induced osteoporosis who are taking hormone replacement.

Original languageEnglish (US)
Pages (from-to)1627-1633
Number of pages7
JournalJournal of Clinical Investigation
Volume102
Issue number8
StatePublished - Oct 15 1998
Externally publishedYes

Fingerprint

Parathyroid Hormone
Osteoporosis
Adrenal Cortex Hormones
Spine
Randomized Controlled Trials
Bone Density
Bone Remodeling
Tomography
X-Rays
Forearm
Hip
Teriparatide
Therapeutics
Hormone Replacement Therapy
Bone Resorption
Osteogenesis
Skeleton
Estrogens
Biomarkers
Hormones

Keywords

  • Corticosteroid-induced osteoporosis
  • Parathyroid hormone treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis : Results of a randomized controlled clinical trial. / Lane, Nancy E; Sanchez, Sarah; Modin, Gunnar W.; Genant, Harry K.; Pierini, Elena; Arnaud, Claude D.

In: Journal of Clinical Investigation, Vol. 102, No. 8, 15.10.1998, p. 1627-1633.

Research output: Contribution to journalArticle

Lane, Nancy E ; Sanchez, Sarah ; Modin, Gunnar W. ; Genant, Harry K. ; Pierini, Elena ; Arnaud, Claude D. / Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis : Results of a randomized controlled clinical trial. In: Journal of Clinical Investigation. 1998 ; Vol. 102, No. 8. pp. 1627-1633.
@article{90401890d2de47f4ac04f0097fe9ea33,
title = "Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial",
abstract = "Corticosteroid-induced osteoporosis is the most common secondary cause of osteoporosis. We conducted a 12-mo, randomized clinical trial of human parathyroid hormone 1-34 (hPTH 1-34) in postmenopausal women (mean age was 63 yr) with osteoporosis who were taking corticosteroids and hormone replacement therapy. Response to the treatment was assessed with bone mineral density (BMD) measurements of the lumbar spine by quantitative computed tomography (QCT); BMD measurements of the lumbar spine, hip, and forearm by dual-energy x-ray absorptiometry (DXA); and biochemical markers of bone turnover. The mean (±SE) changes in BMD of the lumbar spine by QCT and DXA in the PTH group were 35±5.5{\%} and 11±1.4{\%}, respectively, compared with a relatively small change of 1.7±1.8{\%} and 0±0.9{\%} in the estrogen-only group. The differences in mean percentage between the groups at 1 yr were 33.5{\%} for the lumbar spine by QCT (P < 0.001) and 9.8{\%} for the lumbar spine by DXA (P < 0.001). The changes in the hip and forearm were not significantly different between or within the groups. During the first 3 mo of PTH treatment, markers of bone formation increased to nearly 150{\%}, whereas markers of bone resorption increased only 100{\%}, suggesting an early uncoupling of bone turnover in favor of formation. These results suggest that parathyroid hormone dramatically increases bone mass in the central skeleton of postmenopausal women with corticosteroid-induced osteoporosis who are taking hormone replacement.",
keywords = "Corticosteroid-induced osteoporosis, Parathyroid hormone treatment",
author = "Lane, {Nancy E} and Sarah Sanchez and Modin, {Gunnar W.} and Genant, {Harry K.} and Elena Pierini and Arnaud, {Claude D.}",
year = "1998",
month = "10",
day = "15",
language = "English (US)",
volume = "102",
pages = "1627--1633",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "8",

}

TY - JOUR

T1 - Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis

T2 - Results of a randomized controlled clinical trial

AU - Lane, Nancy E

AU - Sanchez, Sarah

AU - Modin, Gunnar W.

AU - Genant, Harry K.

AU - Pierini, Elena

AU - Arnaud, Claude D.

PY - 1998/10/15

Y1 - 1998/10/15

N2 - Corticosteroid-induced osteoporosis is the most common secondary cause of osteoporosis. We conducted a 12-mo, randomized clinical trial of human parathyroid hormone 1-34 (hPTH 1-34) in postmenopausal women (mean age was 63 yr) with osteoporosis who were taking corticosteroids and hormone replacement therapy. Response to the treatment was assessed with bone mineral density (BMD) measurements of the lumbar spine by quantitative computed tomography (QCT); BMD measurements of the lumbar spine, hip, and forearm by dual-energy x-ray absorptiometry (DXA); and biochemical markers of bone turnover. The mean (±SE) changes in BMD of the lumbar spine by QCT and DXA in the PTH group were 35±5.5% and 11±1.4%, respectively, compared with a relatively small change of 1.7±1.8% and 0±0.9% in the estrogen-only group. The differences in mean percentage between the groups at 1 yr were 33.5% for the lumbar spine by QCT (P < 0.001) and 9.8% for the lumbar spine by DXA (P < 0.001). The changes in the hip and forearm were not significantly different between or within the groups. During the first 3 mo of PTH treatment, markers of bone formation increased to nearly 150%, whereas markers of bone resorption increased only 100%, suggesting an early uncoupling of bone turnover in favor of formation. These results suggest that parathyroid hormone dramatically increases bone mass in the central skeleton of postmenopausal women with corticosteroid-induced osteoporosis who are taking hormone replacement.

AB - Corticosteroid-induced osteoporosis is the most common secondary cause of osteoporosis. We conducted a 12-mo, randomized clinical trial of human parathyroid hormone 1-34 (hPTH 1-34) in postmenopausal women (mean age was 63 yr) with osteoporosis who were taking corticosteroids and hormone replacement therapy. Response to the treatment was assessed with bone mineral density (BMD) measurements of the lumbar spine by quantitative computed tomography (QCT); BMD measurements of the lumbar spine, hip, and forearm by dual-energy x-ray absorptiometry (DXA); and biochemical markers of bone turnover. The mean (±SE) changes in BMD of the lumbar spine by QCT and DXA in the PTH group were 35±5.5% and 11±1.4%, respectively, compared with a relatively small change of 1.7±1.8% and 0±0.9% in the estrogen-only group. The differences in mean percentage between the groups at 1 yr were 33.5% for the lumbar spine by QCT (P < 0.001) and 9.8% for the lumbar spine by DXA (P < 0.001). The changes in the hip and forearm were not significantly different between or within the groups. During the first 3 mo of PTH treatment, markers of bone formation increased to nearly 150%, whereas markers of bone resorption increased only 100%, suggesting an early uncoupling of bone turnover in favor of formation. These results suggest that parathyroid hormone dramatically increases bone mass in the central skeleton of postmenopausal women with corticosteroid-induced osteoporosis who are taking hormone replacement.

KW - Corticosteroid-induced osteoporosis

KW - Parathyroid hormone treatment

UR - http://www.scopus.com/inward/record.url?scp=0032532062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032532062&partnerID=8YFLogxK

M3 - Article

C2 - 9788977

AN - SCOPUS:0032532062

VL - 102

SP - 1627

EP - 1633

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -